Oseltamivir (Tamiflu) induced depressive episode in a female adolescent

Psychiatry Investigation

Volumn 7, Issue 4, 2010, Pages 302-304

  Chung, Sungho ^a   Joung, Yoo Sook ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Adolescent; Depressive episode; Oseltamivir

Indexed keywords

ANTIDEPRESSANT AGENT; LITHIUM; OSELTAMIVIR; QUETIAPINE;

ABDOMINAL PAIN; ADOLESCENT; AGITATION; BEHAVIOR DISORDER; CASE REPORT; CONCENTRATION LOSS; CONVULSION; DECISION MAKING; DECREASED APPETITE; DELIRIUM; DELUSION; DEPRESSION; DIARRHEA; DRUG DOSE INCREASE; DRUG TOLERABILITY; FEMALE; HUMAN; INFLUENZA A; INSOMNIA; IRRITABILITY; MANIA; NAUSEA; NERVOUSNESS; PANIC; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOUTH KOREA; SUICIDAL IDEATION; SUICIDE; UNCONSCIOUSNESS; VOMITING;

EID: 79551639009     PISSN: 17383684     EISSN: None     Source Type: Journal    
DOI: 10.4306/pi.2010.7.4.302     Document Type: Review

References (18)

1. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999;282:1240-1246.
2. Jamieson B, Jain R, Carleton B, Goldman RD. Use of oseltamivir in children. Can Fam Physician 2009;55:1199-1201.
3. Lindemann L, Jacobsen H, Schuhbauer D, Knoflach F, Gatti S, Wettstein JG, et al. In vitro pharmacological selectivity profile of oseltamivir prodrug (Tamiflu) and active metabolite. Eur J Pharmacol 2010;628:6-10.
4. Bardsley-Elliot A, Noble S. Oseltamivir. Drugs 1999;58:851-860; discussion 861-862.
5. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355:1845-1850.
6. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127-133.
7. Toovey S, Rayner C, Prinssen E, Chu T, Donner B, Thakrar B, et al. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review. Drug Saf 2008;31:1097-1114.
8. Fuyuno I. Tamiflu side effects come under scrutiny. Nature 2007;446: 358-359.
9. Izumi Y, Tokuda K, O'Dell KA, Zorumski CF, Narahashi T. Neuroexcitatory actions of Tamiflu and its carboxylate metabolite. Neurosci Lett 2007;426:54-58.
10. Ho LN, Chung JP, Choy KL. Oseltamivir-induced mania in a patient with H1N1. Am J Psychiatry 2010;167:350.
11. Okumura A, Kubota T, Kato T, Morishima T. Oseltamivir and delirious behavior in children with influenza. Pediatr Infect Dis J 2006;25:572.
12. Smith JR, Sacks S. Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. Int J Clin Pract 2009;63:596-605.
13. Yorifuji T, Suzuki E, Tsuda T. Oseltamivir and abnormal behaviors: true or not? Epidemiology 2009;20:619-621.
14. Vantine M, Falahee ML, Vallerand AH. Neuropsychiatric concerns related to influenza treatment. Nurse Pract 2009;34:40-44.
15. McClellan K, Perry CM. Oseltamivir: a review of its use in influenza. Drugs 2001;61:263-283.
16. Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C, Ward P. Safety and pharmacology of oseltamivir in clinical use. Drug Saf 2003;26:787-801.
17. Yoshino T, Nisijima K, Shioda K, Yui K, Kato S. Oseltamivir (Tamiflu) increases dopamine levels in the rat medial prefrontal cortex. Neurosci Lett 2008;438:67-69.
18. Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, et al. Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos 2009;37:315-321.